Premier Integrated Labspart of IHH Healthcare Malaysia, has become the first provider to offer the Prosigna test for breast cancer in Malaysia, marking a major milestone in breast cancer care.
The test, crucial for assessing the risk of cancer recurrence, offers patients faster access to first-class diagnostics without the need to send samples abroad. As the sole provider of the Prosigna test in Malaysia, Premier Integrated Labs sets a new standard in precision medicine and reaffirms its commitment to cutting-edge diagnostic services.
Premier Integrated Labs receives the prestigious Univants Award for Healthcare Excellence 2024
Mohd Hareeff Muhammed, CEO of Premier Integrated Labs, said: “By making the Prosigna breast cancer trial available locally, we are ensuring that Malaysian patients can benefit from faster and more personalized information that directly impacts treatment decisions. “This represents a significant leap in improving healthcare for breast cancer patients throughout the country.”
The Prosigna breast cancer test analyzes the activity of specific genes in tumor tissue, providing a personalized risk assessment by examining factors such as tumor size, cell proliferation, and lymph node involvement.
Premier Integrated Labs sets a new standard in precision medicine and reaffirms its commitment to cutting-edge diagnostic services
Using the nCounter Dx testing system, Premier Integrated Labs processes the test locally, eliminating the need to send it to overseas laboratories and ensuring faster results.
Add Comment